14/2022・Trifork Group – Report of the third quarter ending 30 September 2022

In This Article:

Trifork Holding AG
Trifork Holding AG

Company announcement no. 14 / 2022

Schindellegi, Switzerland – 2 November 2022

Trifork Group – Report of the third quarter ending 30 September 2022

Trifork Group: Delivering on organic growth targets in Q3 2022 and continued confirmation of full year guidance

Third quarter of 2022

  • Revenue of Trifork Group ("Trifork”) in the third quarter of 2022 was EURm 43.4, an increase of 17.6% compared to the same period in 2021. Revenue grew organically by 20.3% (adjusted for deconsolidation of Dawn Health) compared to the same period in 2021 and was to a large extent driven by organic growth from Digital Health and Cyber Protection in the Build and Run sub-segments.

  • Trifork segment adjusted EBITDA in Q3 2022 was EURm 7.8 equal to an adjusted EBITDA-margin of 17.9% compared to 16.9% in Q3 2021.

  • The Inspire sub-segment in Q3 recorded revenue of EURm 0.6 which was at the same level as in Q3 2021. Adjusted EBITDA was EURm -0.3.

  • The sub-segment Build recorded revenue increase of 13.8% to EURm 33.9 and an adjusted EBITDA margin of 22.9%. Adjusted for the deconsolidation of Dawn Health, organic revenue growth of the Build sub-segment amounted to 17.1%.

  • The sub-segment Run recorded a solid organic revenue increase of 36.2% to EURm 8.8, compared to EURm 6.4 in Q3 2021. The adjusted EBITDA of EURm 1.7 correspond to an adjusted EBITDA margin of 19.0%.

  • Trifork Group EBIT for Q3 2022 was EURm 4.5 equal to a 10.3% EBIT margin.

  • EBT in Trifork Labs amounted to EURm 1.0 in Q3 2022 compared to EURm 0.1 achieved in Q3 2021. In the quarter, EURm 1.5 was recorded as realized gains.

  • Trifork Group Q3 2022 net income amounted to EURm 4.1, compared to EURm 1.8 in Q3 2021.

First nine months of 2022

  • Revenue of Trifork Group ("Trifork”) in the first nine months of 2022 was EURm 135.1, an increase of 16.2% compared to the same period in 2021. Revenue grew organically by 18.6% (adjusted for deconsolidation of Dawn Health) compared to the first nine months of 2021 and was primarily driven by high organic growth from Fintech, Digital Health and Cyber Protection in the Build and Run sub-segments.

  • Trifork segment adjusted EBITDA was EURm 22.2 in the first nine months of 2022 compared to EURm 21.3 in the same period in 2021. This equals to an adjusted EBITDA margin of 16.4% in the first nine months of 2022. In this period non-capitalized investments of EURm 1.2 were done in the Run sub-segment.

  • Trifork Group EBIT for the first nine months of 2022 was EURm 12.2 an increase of 28.2% from EURm 9.5 in the same period in 2021. This reflecting an 9.0% EBIT margin.

During Q3 our team delivered the first prototype products in collaboration with our customer, to perform first tests in the Swiss digital health environment. By now, it looks promising and we look forward to collaborate with our customer to bring a new modern digital health product successfully to the Swiss market” said Trifork CEO Jørn Larsen and continued, “we also noted impressive growth from our team in the Cyber Protection business area, and we remain positive about the continued demand and development of these services. On the macroeconomic level, we still experience a global instability with increasing inflation and interest rates. Until now we together with our customers have been able to improve the planning and settings in most of our engagements but this not done without any challenges. We remain confident that the services and products we deliver, can support and strengthen our customers ability to tackle the new situations resulting from the instable global business environment.”